<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837003</url>
  </required_header>
  <id_info>
    <org_study_id>MODEL U-SES</org_study_id>
    <nct_id>NCT02837003</nct_id>
  </id_info>
  <brief_title>3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation</brief_title>
  <acronym>MODEL U-SES</acronym>
  <official_title>3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teikyo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teikyo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety of reduction of dual antiplatelet therapy period to three months after
      implantation of Ultimaster sirolimus-eluting stent (U-SES).

      Additionally to investigate appropriateness of thienopyridine monotherapy with
      discontinuation of aspirin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Composite endpoint of all cause death in 12 months, myocardial infarction, stroke (ischemic and hemorrhagic), ARC definite/probable stent thrombosis and serious bleeding (BARC 3 or 5).</measure>
    <time_frame>12-month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint of all cause death in 3 months, myocardial infarction, stroke (ischemic and hemorrhagic), ARC definite/probable stent thrombosis and serious bleeding (BARC 3 or 5).</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause death</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (ischemic and hemorrhagic)</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke (ischemic and hemorrhagic)</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission related to angina</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission related to angina</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis (ARC definition)</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (BARC definition)</measure>
    <time_frame>3-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding complications (BARC definition)</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of event rate by the type of antiplatelet agent</measure>
    <time_frame>12-month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Experimental: Aspirin</arm_group_label>
    <description>Aspirin treatment for 3 months after the Ultimaster sirolimus-eluting stent implantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Thienopyridine</arm_group_label>
    <description>Thienopyridine treatment for 3 months after the Ultimaster sirolimus-eluting Stent implantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.</description>
    <arm_group_label>Experimental: Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thienopyridine</intervention_name>
    <description>Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.</description>
    <arm_group_label>Experimental: Thienopyridine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The present study consisted of the following two study arms: the 3-month DAPT arm, a new
        registry arm in which 1,500 patients are consecutively recruite at 72 medical institutions;
        and the Longer DAPT arm, a historical control arm that consisted of 1,123 patients at 58
        medical institutions.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with coronary artery lesion who received percutaneous coronary intervention
             using Ultimaster sirolimus-eluting stent.

          -  Patients considered appropriate to discontinue dual antiplatelet therapy at 3 months
             after stent implantation.

          -  Patients who have provided written informed consent.

        Exclusion Criteria:

          -  Patients previously experienced stent thrombosis.

          -  Patients who are unable to clinical follow-up procedure specified in the protocal for
             the present study.

          -  Patients who are enrolled or planned to participate in another clinical trials of
             antiplatelet therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ken Kozuma, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Teikyo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ken Kozuma, MD, PhD</last_name>
    <phone>+81-3-3964-1211</phone>
    <email>PXE00364@nifty.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teikyo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>173-8606</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Kozuma, MD, PhD</last_name>
      <phone>+81-3-3964-1211</phone>
      <email>PXE00364@nifty.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2016</study_first_posted>
  <last_update_submitted>July 31, 2016</last_update_submitted>
  <last_update_submitted_qc>July 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Eluting Stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

